New York: Pfizer beat the third quarter expectation and raised an estimated 2021 again even as the sale of the top products, Covid-19 Vaksin Comiraty, sneaking in the US surged preventive shots helped push the total income Komirnaty approached $ 13 billion in the quarter, and the drug maker said On Tuesday that it is now hoping to order around $ 36 billion in sales from this year’s vaccine.
It rises from the second quarter estimate for $ 33.5 billion and more than doubled what Pfizer expected at the beginning of the year.
Pfizer shares the benefits of vaccines and costs to create and distribute them with Bionontech German development partners.
In the US, the third-quarter sales of vaccines fell to $ 1.59 billion from a slightly more than $ 2 billion in the previous quarter.
Analyst estimates that, because demand falls after a hurry to get a shot shortly after the feasibility of the vaccine is expanded in the spring.
But demand seems to increase again and will be assisted by booster shots and the expected authorization for vaccines in children, analyst Mizuho Securities USA, Dr.
Vamil divan said in a recent note.
Last weekend, food administration and medicine cleaned the dose of child size from the Covid-19 Pfizer vaccine – only one third of the amount given to adolescents and adults – for emergency use.
Up to 28 million more American children can qualify for vaccinations this weekend.
Overall, Pfizer obtained $ 8.15 billion in the third quarter, with a total adjusted result with a total of $ 1.34 per share.
The total company revenue is more than doubled to $ 24.09 billion.
Analysts are expected, on average, third-quarter income of $ 1.08 per share from Pfizer at around $ 22.58 billion in income, according to FactSet.
7% operating income in the third quarter did not count the Covid-19 vaccine.
The Pfizer product portfolio also includes several cancer treatments, other vaccines and internal drug drugs such as Eliquis, to prevent blood clots and strokes.
The drug sales rose 21% in the quarter to $ 1.35 billion.
New York-based Pfizer Inc.
now expects 1821 profits adjusted $ 4.13 to $ 4.18 per share on revenues ranging from $ 81 billion to $ 82 billion.
For 2021, analysts expect revenues of $ 4.04 per share at $ 78.77 billion in income.
Pfizer shares rose 4% to $ 45.34 in the morning trade before the market opened.
In August, shares had topped the highest price of $ 47.40, a sign that was established for 22 years.